

Details of Revenue

(Billions of yen)

	2018.3	2019.3	2020.3	2021.3	2022.3	2023.3 (Forecast)
Revenue of Major Products						
OPDIVO Intravenous Infusion	90.1	90.6	87.3	98.8	112.4	155.0
FORXIGA Tablets	11.1	14.5	18.1	22.4	36.7	47.0
GLACTIV Tablets	27.4	26.9	26.1	25.5	24.5	23.0
ORENCIA for Subcutaneous Injection	14.1	17.4	19.8	21.9	22.9	23.0
PARSABIV Intravenous Injection	3.4	5.7	7.1	8.1	8.9	8.0
KYPROLIS for Intravenous Infusion	5.5	4.9	6.0	7.1	8.4	9.0
ONOACT for Intravenous Infusion	5.6	4.6	4.9	4.7	4.9	4.5
OPALMON Tablets	14.4	10.4	8.3	5.5	4.7	3.5
VELEXBRU Tablets	—	—	—	2.1	6.3	7.0
RIVASTACH Patches	8.9	8.9	8.5	6.6	2.9	*
BRAFTOVI Capsules	—	—	*	1.1	2.7	3.5
MEKTOVI Tablets	—	—	*	1.0	2.2	2.5
ONON Capsules	5.5	4.4	3.5	2.9	3.6	2.5
ONGENTYS Tablets	—	—	—	0.3	2.9	5.0

Note: Based on ex-manufacturer prices
* Not disclosed.

Breakdown of Revenue

Revenue of goods and products	205.9	208.9	205.6	214.5	246.0	290.0
Royalty and others	55.9	79.7	86.8	94.7	115.4	135.0
OPDIVO Intravenous Infusion	39.8	58.5	61.6	59.8	69.9	*
Keytruda® (Merck)	*	12.8	19.3	24.3	30.8	*
Other	*	8.4	5.9	10.6	14.7	*

* Not disclosed.

Revenue by Region

Japan	204.0	207.4	202.9	212.9	242.0
Americas	52.5	72.3	81.5	85.6	105.9
Asia	5.1	7.4	7.5	7.4	8.9
Europe	0.2	1.6	0.5	3.4	4.6